Y-mAbs Therapeutics (NASDAQ:YMAB) Receives Outperform Rating from Wedbush

Y-mAbs Therapeutics (NASDAQ:YMAB)‘s stock had its “outperform” rating restated by stock analysts at Wedbush in a research note issued to investors on Monday,RTT News reports. They currently have a $23.00 price target on the stock. Wedbush’s price objective would suggest a potential upside of 343.16% from the stock’s current price.

Several other equities research analysts have also weighed in on the company. HC Wainwright restated a “buy” rating and set a $22.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday, January 13th. Brookline Capital Management began coverage on shares of Y-mAbs Therapeutics in a research report on Thursday, December 5th. They issued a “buy” rating and a $17.00 target price on the stock. Finally, Oppenheimer assumed coverage on shares of Y-mAbs Therapeutics in a research report on Monday, November 18th. They set an “outperform” rating and a $23.00 price target for the company. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $20.89.

Y-mAbs Therapeutics Trading Down 6.7 %

Y-mAbs Therapeutics stock traded down $0.37 during trading hours on Monday, hitting $5.19. 429,703 shares of the stock traded hands, compared to its average volume of 469,408. Y-mAbs Therapeutics has a one year low of $5.13 and a one year high of $19.12. The firm’s 50-day moving average price is $6.58 and its two-hundred day moving average price is $10.72. The company has a market cap of $232.45 million, a PE ratio of -9.61 and a beta of 0.67.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Y-mAbs Therapeutics in the 3rd quarter worth approximately $44,000. KLP Kapitalforvaltning AS bought a new stake in shares of Y-mAbs Therapeutics in the 4th quarter worth $46,000. ProShare Advisors LLC purchased a new position in shares of Y-mAbs Therapeutics in the fourth quarter worth $99,000. Intech Investment Management LLC bought a new position in shares of Y-mAbs Therapeutics during the third quarter valued at $133,000. Finally, Wells Fargo & Company MN boosted its position in shares of Y-mAbs Therapeutics by 54.1% during the fourth quarter. Wells Fargo & Company MN now owns 17,458 shares of the company’s stock valued at $137,000 after buying an additional 6,131 shares during the last quarter. Institutional investors own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.